The Association for Accessible Medicines, which represents generic and biosimilar manufacturers, chose a leader with a research, public relations, and strategic planning background.
Dan Leonard, former president and CEO of the National Pharmaceutical Council (NPC), has been named president and CEO of the generic and biosimilar industry trade group Association for Accessible Medicines (AAM), effect September.
He succeeds Chester “Chip” Davis Jr, who left AAM in February 2020. AAM represents manufacturers and distributors of generic pharmaceuticals, biosimilars, and bulk pharmaceutical chemicals. Its membership includes suppliers of other goods and services to the generic industry.
Within AAM is the Biosimilars Council, which works to improve biosimilar awareness and uptake with an emphasis on public and health expert education, government affairs, legal affairs, and regulatory policy.
At the NPC, Leonard helped with the group's mission to develop pharmaceutical and pharmaceutical innovation through research and sponsorship of research. Previously, Leonard was executive vice president of advocacy and professional services for America’s Health Insurance Plans, a trade association that represents US payers.
He is a regularly published columnist with Chain Drug Review. In a recent column, Leonard highlighted the challenges to ensuring access to health care for populations affected by coronavirus disease 2019 (COVID-19). He predicted increased Medicaid enrollment leading to challenges for states with limited budgets.
Members of AAM expressed confidence in Leonard’s abilities to lead group toward greater success. “Dan’s decades of leadership experience across the pharmaceutical ecosystem and his unparalleled background in policy and communications make him the perfect person to lead our industry’s efforts to advocate for policies to increase patient access to generic and biosimilar medicines through greater competition,” said Alok Sonig, chairman of the AAM Board of Directors and CEO, US Generics and Head, Global R&D and Biosimilars, Lupin.
Leonard’s background includes more than 20 years of experience in strategic communications, legislative management, politics, and broadcast journalism. During the search for Davis’ replacement, AAM was helmed by its senior vice president and general counsel, Jeff Francer.
Empowering Vulnerable Populations: The Path to Equitable Biologic Therapy Access
December 22nd 2024Elie Bahou, PharmD, senior vice president and system chief pharmacy officer at Providence, discusses strategies to improve equitable access to biologic therapies, including tiered formularies, income-based cost sharing, patient assistance programs, and fostering payer partnerships.
Biosimilars Policy Roundup for September 2024—Podcast Edition
October 6th 2024On this episode of Not So Different, we discuss the FDA's approval of a new biosimilar for treating retinal conditions, which took place in September 2024 alongside other major industry developments, including ongoing legal disputes and broader trends in market dynamics and regulatory challenges.
Health Canada Approves First Omalizumab Biosimilar
December 16th 2024Health Canada has approved Omlyclo, the first omalizumab biosimilar in Canada, for the treatment of chronic idiopathic urticaria, allergic asthma, and chronic rhinosinusitis with nasal polyps, based on a phase 3 study confirming its bioequivalence to the reference product.
Eye on Pharma: Golimumab Biosimilar Update; Korea Approves Denosumab; Xbrane, Intas Collaboration
December 10th 2024Alvotech and Advanz Pharma have submitted a European marketing application for their golimumab biosimilar to treat inflammatory diseases, while Celltrion secured Korean approval for denosumab biosimilars, and Intas Pharmaceuticals partnered with Xbrane Biopharma on a nivolumab biosimilar.
Commercial Payer Coverage of Biosimilars: Market Share, Pricing, and Policy Shifts
December 4th 2024Researchers observe significant shifts in payer preferences for originator vs biosimilar products from 2017 to 2022, revealing growing payer interest in multiple product options, alongside the increasing market share of biosimilars, which contributed to notable reductions in both average sales prices and wholesale acquisition costs.